- Organizations: Beacon Therapeutics
Pipeline
FDA grants RMAT designation to Beacon Therapeutics XLRP gene therapy
Laru-zova (AGTC-501) targets the full expression of the RPGR protein, with clinical data reporting its safety, tolerance, and robust visual function improvement effects.
Pipeline
Beacon Therapeutics reports positive 24-month phase 2 XLRP gene therapy data
Latest findings demonstrate AGTC-501 to be generally safe and well-tolerated, with a 57% response rate noted among high-dose-treated eyes.
Pipeline
Beacon Therapeutics to evaluate patented AAV gene therapy for retinal diseases
Licensing agreement involves potential development and commercialization of Abeona Therapeutics’ patented capsid, a pan-retinal-administered vector.
Pipeline
Beacon Therapeutic raises $170M for XLRP gene therapy development
Funding supports clinical trials on AGTC-501, lead asset designed to address all photoreceptor damage caused by XLRP.
Pipeline
Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial
Randomized study is investigating AGTC-501 for the treatment of patients diagnosed with x-linked retinitis pigmentosa.
Pipeline
Beacon Therapeutics releases positive 12-month data from phase 2 XLRP trial
Latest results find AGTC-501 gene therapy to be safe and well tolerated, demonstrating robust visual function improvements.
Business